Objective:To design a novel model for experiments on in vitro irradiation with radioactive seeds using a treatment planning system (TPS) and 3D printing technology and to preliminarily validate the design scientific rigor of the model via experiments on isodose brachytherapy (BT) and external beam radiotherapy (EBRT) on glioma cells in mice. Methods:The TPS was employed to design the model′s shape and calculate the number and positions of radioactive seeds, and 3D printing technology was utilized to fabricate the experimental model. The GL261 cell line was selected for in vitro irradiation experiments, with the mice divided into the control, EBRT, and BT groups. Mice in the EBRT and BT groups were treated with EBRT and BT, respectively, at doses of 2, 4, and 6 Gy. Then, changes in their cell viability, proliferation, and the level of intracellular reactive oxygen species (ROS) were assessed. Results:The model for in vitro irradiation with radioactive seeds was successfully designed and fabricated. The single photon emission computed tomography (SPECT) verified a uniform radioactive distribution within the model, with no significant cold spots. The BT and EBRT groups displayed decreased cell viability with an increase in the radiation dose. Compared to the EBRT group, the BT group exhibited significantly reduced cell viability (51.33% vs. 22.00%, t = 10.94, P < 0.05) and clone counts (172.67 ± 13.11 vs. 53.67 ± 10.22, t = 8.73, P < 0.05), but a significantly increased level of ROS (102.52 ± 6.87 vs. 144.81 ± 6.01, t = -5.26, P < 0.05) at a dose of 6 Gy. Conclusions:An effective model of in vitro irradiation with radioactive seeds is designed based on TPS and 3D printing technology. This provides an experimental model tool and target for research on the BT and EBRT mechanisms.

Objective:To employ single-photon emission computed tomography (SPECT)/CT for isodose assignment in 125I brachytherapy, assess the correlation between photon counts and dose values, and develop a clinical γ-ray visualization model for 125I brachytherapy. Methods:125I radioactive seeds were filled into a self-made 3D printed stereotactic template to build a stereotactic model. The model was scanned by SPECT/CT for photon counts at 0.5, 1.0, 1.5, 2.0 cm from the outermost peripheral seeds, and the corresponding dose values were measured using the Treatment Planning System (TPS). The fitting curve for the photon counts and the dose values was plotted using SPSS 27.0 software. Results:The photon counts of γ rays at distances of 0.5, 1.0, 1.5, and 2.0 cm from the peripheral particles were 7 603.57±1 806.35, 4 018.26±1 315.72, 2 074.04±791.53, and 1 080.34±424.79, respectively, showing a significant difference ( F=743.72, P<0.01). The dose values (in Gy) in the TPS at distances of 0.5, 1.0, 1.5, and 2.0 cm from the peripheral particles were 208.05±37.57, 125.43±17.74, 86.76±17.67, and 61.55±14.39, respectively, which were significantly different ( F=930.46, P<0.01). The photon counts were linearly correlated with the dose values ( y=0.02 x+ 46.45, R2=81.2%, P<0.01). Conclusions:SPECT/CT-based γ-ray photon count detection can be used to assign doses for 125I brachytherapy, enabling the visualization of γ rays in 125I brachytherapy. This approach has a distinct advantage over TPS, laying the foundation for the establishment of an alternative system to TPS.

Objective:To evaluate the sample preparation proficiency and storage proficiency of 11 clinical biobanks in Beijing through simulated experiments, and to establish an assessment method for the quality comparability of biological samples.Methods:An exploratory research design was adopted. In November 2023, artificial composite serum quality control materials containing six recombinant human protein markers—recombinant human alanine aminotransferase (rhALT), recombinant human aspartate aminotransferase (rhAST), recombinant human creatine kinase (rhCK), recombinant human creatine kinase-MB (rhCK-MB), recombinant human B-type natriuretic peptide (rhBNP), and recombinant human troponin I (rhTNI)—were distributed to 11 clinical biobanks in Beijing City. Sample preparation and storage followed the standardized operating procedures. Proficiency differences were assessed through statistical analysis.Results:Three-way repeated measures ANOVA revealed all six protein markers showed a declining trend over storage time in ultra-low-temperature environments ( F values 11.68-4 179.66, all P<0.01). However, neither long-term/temporary refrigerator types ( F values 0.01-1.23, all P>0.05)nor placement locations within refrigerators significantly affected the stability of these six proteins ( F valus 0.03-1.47, all P>0.05). The biases in detection results for rhALT, rhAST, rhTNI, and rhBNP at different storage time points were within the allowable bias limits for each item, supporting their use as markers for protein stability in biobank samples. All 11 institutions passed the storage proficiency assessment. In the preparation proficiency assessment, deviations were observed in post-preparation sample results, with a notably high out-of-control rate for rhCK (36.36%). Conclusion:Sample preparation proficiency can serve as a quality control metric for clinical biobanks. Future external quality assessment systems for biobanks should focus on sample preparation rather than storage processes.

Objective Develop a general patient-reported outcome(PRO)measure for cancer patients,which will be suitable for Chinese demographic characteristics.It can reflect disease burden from patients' perspective.Methods Theoretical framework of the PRO measure was constructed according to the PRO guide draft.The initial version of the PRO measure was formed after literature search,experts' consultation,and recognition tests of patients.The pre-survey and formal survey were conducted respectively in provincial,municipal,county level hospitals.Items were screened by the combination of classical test theory and item response theory.Its reliability,validity and feasibility were analyzed.The minimal detectable change of three domains were estimated using a distribution-based methods.Results A total of 2213 valid questionnaires were collected.The demographic data of cancer patients and non-cancer patients were comparable(P＞0.05).19 items were deleted after classical test theory.Item responsiveness of four disease systems were analyzed by the Bayesian item response theory.Four items were deleted.The formal PRO measure included 4 domains,13 dimensions and 49 items.And its reliability,validity and feasibility results met the expected criteria.The minimal detectable change in physiological,psychological and social domains were 5.63,3.42 and 4.16,respectively.Conclusion The general PRO measure for cancer patients was reliable and feasible.The tool can effectively measure and evaluate the quality of life for cancer patients.

Objective:To design a novel model for experiments on in vitro irradiation with radioactive seeds using a treatment planning system (TPS) and 3D printing technology and to preliminarily validate the design scientific rigor of the model via experiments on isodose brachytherapy (BT) and external beam radiotherapy (EBRT) on glioma cells in mice. Methods:The TPS was employed to design the model′s shape and calculate the number and positions of radioactive seeds, and 3D printing technology was utilized to fabricate the experimental model. The GL261 cell line was selected for in vitro irradiation experiments, with the mice divided into the control, EBRT, and BT groups. Mice in the EBRT and BT groups were treated with EBRT and BT, respectively, at doses of 2, 4, and 6 Gy. Then, changes in their cell viability, proliferation, and the level of intracellular reactive oxygen species (ROS) were assessed. Results:The model for in vitro irradiation with radioactive seeds was successfully designed and fabricated. The single photon emission computed tomography (SPECT) verified a uniform radioactive distribution within the model, with no significant cold spots. The BT and EBRT groups displayed decreased cell viability with an increase in the radiation dose. Compared to the EBRT group, the BT group exhibited significantly reduced cell viability (51.33% vs. 22.00%, t = 10.94, P < 0.05) and clone counts (172.67 ± 13.11 vs. 53.67 ± 10.22, t = 8.73, P < 0.05), but a significantly increased level of ROS (102.52 ± 6.87 vs. 144.81 ± 6.01, t = -5.26, P < 0.05) at a dose of 6 Gy. Conclusions:An effective model of in vitro irradiation with radioactive seeds is designed based on TPS and 3D printing technology. This provides an experimental model tool and target for research on the BT and EBRT mechanisms.

Objective:To employ single-photon emission computed tomography (SPECT)/CT for isodose assignment in 125I brachytherapy, assess the correlation between photon counts and dose values, and develop a clinical γ-ray visualization model for 125I brachytherapy. Methods:125I radioactive seeds were filled into a self-made 3D printed stereotactic template to build a stereotactic model. The model was scanned by SPECT/CT for photon counts at 0.5, 1.0, 1.5, 2.0 cm from the outermost peripheral seeds, and the corresponding dose values were measured using the Treatment Planning System (TPS). The fitting curve for the photon counts and the dose values was plotted using SPSS 27.0 software. Results:The photon counts of γ rays at distances of 0.5, 1.0, 1.5, and 2.0 cm from the peripheral particles were 7 603.57±1 806.35, 4 018.26±1 315.72, 2 074.04±791.53, and 1 080.34±424.79, respectively, showing a significant difference ( F=743.72, P<0.01). The dose values (in Gy) in the TPS at distances of 0.5, 1.0, 1.5, and 2.0 cm from the peripheral particles were 208.05±37.57, 125.43±17.74, 86.76±17.67, and 61.55±14.39, respectively, which were significantly different ( F=930.46, P<0.01). The photon counts were linearly correlated with the dose values ( y=0.02 x+ 46.45, R2=81.2%, P<0.01). Conclusions:SPECT/CT-based γ-ray photon count detection can be used to assign doses for 125I brachytherapy, enabling the visualization of γ rays in 125I brachytherapy. This approach has a distinct advantage over TPS, laying the foundation for the establishment of an alternative system to TPS.

Objective:To evaluate the sample preparation proficiency and storage proficiency of 11 clinical biobanks in Beijing through simulated experiments, and to establish an assessment method for the quality comparability of biological samples.Methods:An exploratory research design was adopted. In November 2023, artificial composite serum quality control materials containing six recombinant human protein markers—recombinant human alanine aminotransferase (rhALT), recombinant human aspartate aminotransferase (rhAST), recombinant human creatine kinase (rhCK), recombinant human creatine kinase-MB (rhCK-MB), recombinant human B-type natriuretic peptide (rhBNP), and recombinant human troponin I (rhTNI)—were distributed to 11 clinical biobanks in Beijing City. Sample preparation and storage followed the standardized operating procedures. Proficiency differences were assessed through statistical analysis.Results:Three-way repeated measures ANOVA revealed all six protein markers showed a declining trend over storage time in ultra-low-temperature environments ( F values 11.68-4 179.66, all P<0.01). However, neither long-term/temporary refrigerator types ( F values 0.01-1.23, all P>0.05)nor placement locations within refrigerators significantly affected the stability of these six proteins ( F valus 0.03-1.47, all P>0.05). The biases in detection results for rhALT, rhAST, rhTNI, and rhBNP at different storage time points were within the allowable bias limits for each item, supporting their use as markers for protein stability in biobank samples. All 11 institutions passed the storage proficiency assessment. In the preparation proficiency assessment, deviations were observed in post-preparation sample results, with a notably high out-of-control rate for rhCK (36.36%). Conclusion:Sample preparation proficiency can serve as a quality control metric for clinical biobanks. Future external quality assessment systems for biobanks should focus on sample preparation rather than storage processes.

Objective Develop a general patient-reported outcome(PRO)measure for cancer patients,which will be suitable for Chinese demographic characteristics.It can reflect disease burden from patients' perspective.Methods Theoretical framework of the PRO measure was constructed according to the PRO guide draft.The initial version of the PRO measure was formed after literature search,experts' consultation,and recognition tests of patients.The pre-survey and formal survey were conducted respectively in provincial,municipal,county level hospitals.Items were screened by the combination of classical test theory and item response theory.Its reliability,validity and feasibility were analyzed.The minimal detectable change of three domains were estimated using a distribution-based methods.Results A total of 2213 valid questionnaires were collected.The demographic data of cancer patients and non-cancer patients were comparable(P＞0.05).19 items were deleted after classical test theory.Item responsiveness of four disease systems were analyzed by the Bayesian item response theory.Four items were deleted.The formal PRO measure included 4 domains,13 dimensions and 49 items.And its reliability,validity and feasibility results met the expected criteria.The minimal detectable change in physiological,psychological and social domains were 5.63,3.42 and 4.16,respectively.Conclusion The general PRO measure for cancer patients was reliable and feasible.The tool can effectively measure and evaluate the quality of life for cancer patients.

With the rapid development of preimplantation genetic testing (PGT) technology in recent years, risks in clinical application have arisen at the same time. Related risks include identification of pathogenic variants for PGT, negative impact of disease for PGT on ovarian reservation in female carriers, control of ovarian stimulation, and safety of ovarian simulation in hereditary cancer gene carriers. Risk management should be performed in different steps of the PGT processes.

With the rapid development of preimplantation genetic testing (PGT) technology in recent years, risks in clinical application have arisen at the same time. Related risks include identification of pathogenic variants for PGT, negative impact of disease for PGT on ovarian reservation in female carriers, control of ovarian stimulation, and safety of ovarian simulation in hereditary cancer gene carriers. Risk management should be performed in different steps of the PGT processes.